BGM0504
Asset
Activates GLP-1 and GIP receptors to improve glucose control and reduce body weight.
- Stage
- Phase 3
- Modality
- Peptide
- Target
- Insulin/IGF-1 signalling
- 8
- Indications
- 11
- Trials
- 2
- Developers
Indications
8Type 2 diabetes
Phase 3, Recruiting, NCT07743983, clinicaltrials.gov, 16 Oct 2026
Obesity
Phase 2, Completed, NCT06911203, clinicaltrials.gov, 15 Oct 2026
Overweight
Phase 2, doi.org, 17 Sept 2026
5 more
In the full profile
- Targets and what it contains4
- Owner and partners2
- Trials11
- Evidence for its targets5
- Competitors12
- Aging relevance1
- Signals9
Every asset’s record: target, stage, trials and the evidence behind it.